Evidence map›Paper›PMID 41801992›Full record

ArticlePloS one2026

Assessment of current good manufacturing practice (cGMP) compliance in pharmaceutical manufacturers in Ethiopia: Cross-sectional descriptive study.

Teka Benti Adola, Desta Assefa, Fikadu Ejeta, Fanta Gashe, Getahun Paulos, Dereje Kebebe Borga

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Teka Benti AdolaSchool of Pharmacy, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.ORCID https://orcid.org/0009-0001-8314-4872
Desta AssefaSchool of Pharmacy, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
Fikadu EjetaSchool of Pharmacy, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
Fanta GasheSchool of Pharmacy, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
Getahun PaulosSchool of Pharmacy, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
Dereje Kebebe BorgaSchool of Pharmacy, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe distribution of low-quality medications poses a serious risk to public health, especially in underdeveloped nations like Ethiopia. Ineffective use of Current Good Manufacturing Practices (cGMP) increases these dangers, which include cross-contamination, mix-ups, and incorrect labeling. To ensure consistent product quality and adherence to set standards, a Pharmaceutical Quality System (PQS) that effectively integrate cGMP is essential. Assessing cGMP compliance is essential for the reliable production of safe pharmaceuticals.

objectiveThis study aims to assess cGMP compliance in Ethiopian pharmaceutical manufacturers.

methodsA cross-sectional descriptive design was employed for this study. The data collection process involved a checklist for field observations and, interview-based questions. The checklist, developed based on WHO GMP requirements, was filled through direct site observations, document reviews, and discussions with key persons in the appropriate departments. The study included six companies located in Addis Ababa and its surrounding areas. The qualitative data were transformed into quantitative data through coding and categorization for easier analysis. The data were then analyzed using descriptive statistics, cross-tabulation, and other statistical tests with SPSS software version 28. The results were displayed using data visualization tools like tables and graphs.

resultsThe study revealed overall cGMP compliance rates of 62.8%, 85.84%, 84.95%, 86.72%, 84.95%, and 84.1% for companies 1-6, respectively. All companies had some degree of GMP non-conformity; however, only Company 1 had critical deviations. The GMP standards were well-maintained by the remaining five companies. Company 1 has to make improvements in several areas, most notably its QA systems. Additionally, Companies 1, 5, and 6 must improve their QRM systems. Company 5 needs to improve its production process, while Companies 1, 2, and 3 should focus on better managing their equipment and materials. CONCLUSION AND RECOMMENDATION: This study evaluated GMP compliance levels across six pharmaceutical manufacturers in Ethiopia. Most of the assessed companies showed a satisfactory degree of GMP compliance. To improve compliance, minimize risks, and ensure product quality, safety, and operational efficiency, the study suggested strengthening risk mitigation measures such as raising employees' knowledge and training.

Indexed as

Drug IndustryGuideline AdherenceCross-Sectional StudiesEthiopiaHumansPharmaceutical PreparationsQuality ControlPharmaceutical Preparations

Identifiers

PMID41801992
PMCPMC12970858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.